Ten pharmaceutical companies team up to accelerate new medicines development

Published: 20-Sep-2012
Regulatory Research & Development

TransCelerate BioPharma aims to solve common drug development challenges


Ten leading European and US drug companies have formed a non-profit organisation to accelerate the development of new medicines.

Abbott, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Pfizer, Roche and Sanofi have established TransCelerate BioPharma, said to be the largest initiative of its kind, with the aim of improving the quality of clinical studies and bringing new medicines to patients faster.

Each company will combine financial and other resources, including personnel, to solve industry-wide problems. They have agreed to specific outcome-oriented objectives and have established guidelines for sharing information and expertise to advance collaboration.

Newly appointed acting ceo of TransCelerate BioPharma , Garry Neil, a partner at Apple Tree Partners and formerly corporate vp of science and technology at Johnson & Johnson, said: ‘There is a critical need to increase substantially the number of innovative new medicines, while eliminating inefficiencies that drive up r&d costs.’

‘Our mission at TransCelerate BioPharma is to work together across the global research and development community and share research and solutions that will simplify and accelerate the delivery of exciting new medicines for patients.’

TransCelerate members will initially look at the execution of clinical trials and have selected five projects for funding and development, including: developing a standard methodology for collecting data from patient tests, mutual recognition of study site qualification and training, developing a risk-based site monitoring approach and standards, developing clinical data standards, and establishing a comparator drug supply model.

TransCelerate will also collaborate with several industry groups, as well as government regulators including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA), and contract research organisations.

Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, said the collaboration has the promise ‘to strengthen the industry and its ability to develop innovative and much-needed therapies for patients’.

  • Companies:
  • GlaxoSmithKline
  • Eli Lilly
  • Boehringer Ingelheim
  • Johnson and Johnson
  • Pfizer
  • Sanofi
  • Abbott Laboratories
  • AstraZeneca
  • Roche Group
  • Bristol-Myers Squibb
See more

You may also like

Research & Development

AstraZeneca to acquire Amolyt Pharma for up to $1.05 billion

Read more
The acquisition will facilitate the development of novel therapeutics for rare endocrine and related diseases

Trending Articles

  1. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena
  2. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  3. ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year The award recognises employers that create an outstanding experience for employees
  4. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
  5. Wacker Chemical Corporation promotes Christoph Kowitz to President of US subsidiary The position originally held by David Willhoit is a promotion from Christoph's six year tenure as the Head of Corporate R&D

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Research & Development

AstraZeneca to acquire Amolyt Pharma for up to $1.05 billion

The acquisition will facilitate the development of novel therapeutics for rare endocrine and related diseases
Research & Development

Fasenra could initiate remission in patients with EGPA, study finds

MANDARA Phase III data highlights remission as an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with monthly subcutaneous injections of Fasenra
Manufacturing

Sodexo and AstraZeneca extend global partnership

Sodexo reinforces its contract of food and facilities management services with AstraZeneca in the UK, and Scandinavia for a further five years
Research & Development

Boehringer Ingelheim licenses multiple Dark Antigens from Enara Bio to develop immunotherapies for NSCLC

Dark Antigens are a rich source of novel cancer-specific targets derived from regions of the genome historically thought to be non-coding, known as the genomic dark matter
Research & Development

Elekta and Bristol Myers Squibb partner on digital solution for patients with melanoma

Elekta announces a pilot collaboration with Bristol Myers Squibb to develop a digital solution for patients with melanoma.
Research & Development

Third cancer drug success for Astex drug discovery collaboration

AstraZeneca’s Truqap™ (capivasertib) in combination with Faslodex® (fulvestrant) receives US FDA marketing approval for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer with one or more biomarker alterations (PIK3CA, AKT1 or PTEN)
Research & Development

Redwire’s Lab-in-a-Box aims to leverage the ISS National Lab to improve drug manufacturing
Subscribe now